Sunitinib and Everolimus in Pancreatic Neuroendocrine                     Tumors

Procopio, Giuseppe; Pusceddu, Sara; Buzzoni, Roberto

doi:10.1177/030089161209800319

Cited by 4 publications

(1 citation statement)

References 6 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A bulk of preclinical evidence has shown that the PI3K/AKT/mTOR signaling pathway plays a central role in the pathogenesis and progression of NETs [Manfredi et al 2015;Yao et al 2008;Pusceddu et al 2016a;Procopio et al 2012;Pusceddu et al 2016]. Everolimus is a direct inhibitor of this pathway, and therefore this molecule appear to be a well-grounded strategy for the treatment of NETs, capable of changing clinical practice.…”

Section: Introductionmentioning

confidence: 99%

Everolimus treatment for neuroendocrine tumors: latest results and clinical potential

et al. 2017

Self Cite

View full text Add to dashboard Cite

Neuroendocrine tumors (NETs) are a heterogeneous class of diseases characterized by challenging management. Preclinical evidence shows that the PI3K/AKT/mTOR signaling pathway plays a central role in the pathogenesis and progression of NETs. Everolimus is a direct inhibitor of this pathway, and therefore this molecule appears to be a well-grounded strategy for the treatment of NETs, capable of changing clinical practice. The efficacy and safety of everolimus was demonstrated in the RADIANT trials. In this work, we comment on the results of the RADIANT trials, and other recent key evidence from fully published clinical trials on everolimus, and we discuss the current role of everolimus in the treatment of NETs.

show abstract

Section: Introductionmentioning

confidence: 99%

Everolimus treatment for neuroendocrine tumors: latest results and clinical potential

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

Update in clinical management for gallbladder neuroendocrine carcinoma

et al. 2021

View full text Add to dashboard Cite

Background: Gallbladder neuroendocrine carcinoma (GB-NEC) is rare and there are few reports at present. We sought to review the current knowledge of GB-NEC and provide recommendations for clinical management. Methods: A systemic literature research was conducted in the websites of Pubmed, Medline, Web of Science, CNKI, Wanfang Data using the keywords including gallbladder combined with neuroendocrine carcinoma or neuroendocrine tumor or neuroendocrine neoplasm. Two reviewers independently screened the articles by reading the title, abstract and full-text. Results: In computed tomography (CT) and magnetic resonance imaging (MRI) examination, a well-defined margin, gallbladder replacing type with larger hepatic and lymphatic metastases could be helpful for differential diagnosis of GB-NEC and gallbladder adenocarcinoma (GB-ADC). Older age, unmarried status, large tumor size (>5 cm), positive margins, and distant Surveillance, Epidemiology and End result (SEER) stage are independently associated with poor survival. Surgical resection remains as the preferred and primary treatment. The potential survival benefit of lymphadenectomy for patients remains controversial. Platinum-based postoperative adjuvant chemotherapy may improve the survival. The efficacy of other treatments including immunotherapy, targeted therapy and somatostatin analogue needs further investigation. Conclusion: Typical imaging features could be helpful for preoperative diagnosis. Age, margin status, tumor size, marital status, histopathologic subtype and SEER stage may be independent predictors for the survival. Remarkable advances regarding the treatment for GB-NEC have been achieved in recent years. Further studies are needed to investigate the survival benefit of lymphadenectomy for patients with GB-NEC.

show abstract

Article Commentary: Everolimus in Advanced Solid Tumors: When to Start, Early or Late?

et al. 2014

View full text Add to dashboard Cite

Everolimus is an oral derivative of rapamycin which acts as a signal transduction inhibitor. It targets the mammalian target of rapamycin (mTOR), a key serine/threonine kinase regulating cell growth and angiogenesis. Everolimus has been approved for the treatment of pancreatic neuroendocrine tumors (pNETs), metastatic renal cell carcinoma (mRCC), and breast carcinoma. The activity of everolimus was demonstrated in three phase III randomized placebo-controlled trials, RADIANT-3, RECORD 1 and BOLERO 2, in patients with pNETs, mRCC and breast carcinoma, respectively. All three trials reported a statistically significant increase in median progression-free survival, the primary endpoint of the studies, in favor of everolimus. The absence of an overall survival benefit could be related to the cross-over design and subsequent therapies. The focus of our paper is on the best timing to start treatment with everolimus, while additional questions concern the opportuneness of intermittent use of everolimus specifically in long-responding patients. Lastly, we suggest this treatment could be optimized on the basis of patient and disease characteristics.

show abstract

Sunitinib and Everolimus in Pancreatic Neuroendocrine Tumors

Cited by 4 publications

References 6 publications

Everolimus treatment for neuroendocrine tumors: latest results and clinical potential

Everolimus treatment for neuroendocrine tumors: latest results and clinical potential

Update in clinical management for gallbladder neuroendocrine carcinoma

Article Commentary: Everolimus in Advanced Solid Tumors: When to Start, Early or Late?

Contact Info

Product

Resources

About